Tag: immunotherapy

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition

BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted...

Florida Cancer Specialists & Research Institute Announces Addition Of Specialized Gynecologic Oncology Services in Tampa Bay Communities

Heather Miller, MD Joins Statewide Practice FORT MYERS, Fla., July 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) ) is pleased...

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsImmunotherapy

Invitation to Vitrolife Group’s presentation of the Q2 2025 interim report

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified

RedCloud Announces Pricing of $13.5 Million Private Placement of Securities

Tag: immunotherapy

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition

Florida Cancer Specialists & Research Institute Announces Addition Of Specialized Gynecologic Oncology Services in Tampa Bay Communities

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

Finding Suggests Treatment Approach for Autoimmune Diseases

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us